echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 155 biopharmaceutical companies raise drug prices!

    155 biopharmaceutical companies raise drug prices!

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    CompilationFan Dongdong

    Despite opposition from the U.
    government and patients, most pharmaceutical companies increase the prices of their pharmaceutical products year by year, and this year was no exception

    According to the latest report from the prescription drug price comparison platform GoodRx, between December 29 last year and January 31 this year, at least 155 biomanufacturing companies raised drug prices, with an average price increase of 5.


    Top 10 drugs with rising prices

    Some of the more well-known and expensive brands, such as the anti-PD-1 drugs Opdivo and Jemperli, have previously been known for their expensive prices, and the prices of these two therapies are They rose again in the new year, with gains of 2% and 2.
    5%, respectively

    Opdivo price increases have followed the trend of the past two years, with a net increase of 5.
    1% in Opdivo prices since 2020

    AbbVie's Humira and Humira's potential successors, Rinvoq and Skyrizi, are up roughly 7.
    4% this year


    In addition, although the increase of some drugs in a single year may seem small, the accumulation of multi-year increases will also have a larger impact on the final price
    Taking the acne drug Azalex as an example, GoodRx said that the price of the drug has risen by an astonishing 91.
    7% in the two years from 2020 to 2022.
    The nearly doubling of the increase also puts the drug at the top of the list of drug price increases

    It was followed by the new ophthalmic anti-inflammatory drug Ilevro Ophthalmic Suspension 0.
    3%, which is used to treat pain and inflammation associated with cataract surgery, up 82.


    The third and fourth places on the list are Tazorac and Sulfasalazine (sulfasalazine), both of which have increased by more than 60%.
    The fifth is the gastroenterology drug Zenpep acquired by Nestlé's acquisition of Allergan, with an increase of 2.

    The five drugs ranked sixth to tenth were Movantik, a new constipation drug co-operated by AstraZeneca and Daiichi Sankyo, with an increase of 49.
    5%; Novartis' new dry eye drug Xiidra, an increase of 40.
    1%; tumor drug Nerlynx, Up 39.
    4%; nimodipine oral solution Nymalize, up 38%; and pancreatitis drug Viokace, up 32.


    However, GoodRx researchers also pointed out that the price increase data for some drugs is limited to the list price.
    In reality, there may be no entity paying for it.
    The final price of the drug is also affected by various payment mechanisms and various participants, including insurance.
    Company and manufacturer rebates,

    According to GoodRx, when a manufacturer raises the price of a drug, the corresponding insurer may be forced to pay more for the drug, which may result in insurers passing it on to patients in the form of higher insurance costs, which are commonly used Means include raising insurance premiums or increasing co-payments


    Reference: A new report tracks hundreds of new drug price hikes, along with a look at the top 10

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.